Keywords
How to Cite
Abstract
One of the initiating mutations in the development of thyroid cancer is BRAF-V600E, which leads to the various signaling cascades activation and changes in the production of transcription and growth factors. It is known that papillary thyroid cancer is characterized by activation of the expression of transcription factors NF-kB and HIF-2a and AKT/m-TOR signaling cascade. However, the relationship of the studied molecular markers in patients with the wild and mutant BRAF gene has not yet been studied.
The aim of the work was to study the expression of transcription factors NF-65B p65 and NF-kB p50, HIF-1a, HIF-2a, growth factors VEGF, CAIX and VEGFR2, components of the AKT/m-TOR signaling pathway in patients with thyroid papillary cancer depending on the presence of mutations BRAF-V600E.
Material and methods. It was included 40 patients with papillary thyroid cancer with the stage of the tumor process T1-4N0-2M0. The expression of the indicators was determined by real-time PCR. BRAF-V600E mutation was revealed by allele-specific PCR in real-time.
Results and discussion. It was found that patients with the absence and presence of the BRAF-V600E mutation had similar clinical and morphological parameters of the disease, which was accompanied by a change in the molecular-biological characteristics of the tumor. The presence of the mutant form of the gene in the tumor led to a decrease in the AKT, cRAF, GSK-3P kinases mRNA levels and the overexpression of NF-kB p65, HIF-1 and VEGF.
Conclusion. Patients with papillary thyroid cancer have no differences in the clinical and morphological characteristics of the disease, depending on the status of the BRAF-V600E gene, is characteristic. It was identified biological parameters associated with this somatic mutation. An increase in the mRNA level of growth and transcription factors was observed with a decrease in the activity of the AKT / m-TOR signaling pathway.
References
Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). / Под ред. Каприна А.Д., Старинского В.В., Петровой ГВ. - М.: МНИОИ им. П.А. Герцена, 2018
Kim WW, Ha TK, Bae SK. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol Head Neck Surg. 2018;47(1):4. Published 2018 Jan 9. DOI: 10.1186/s40463-017-0247-6
Faustino A, Couto JP, Populo H, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012;97(7):E1139-49. DOI: 10.1210/jc.2011-2748
Margalef P, Colomer C, Villanueva A. et al. BRAF-induced tumorigenesis is IKKa-dependent but NF-kB-independent. Sci Signal. 2015;8(373):ra38. DOI: 10.1126/scisignal.2005886
Tanaka TN, Alloju SK, Oh DK. et al. Thyroid cancer: molecular pathogenesis, tyrosine kinase inhibitors, and other new therapies. The American journal of hematology/ oncology. 2015;11(4):5-9.
Tavares C, Eloy C, Melo M, et al. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and SLC5A5 mRNA Expression. Int J Mol Sci. 2018;19(5):1448. DOI: 10.3390/ijms19051448
Marotta V, Sciammarella C, Capasso M, et al. Erratum to: Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine. 2017;57(3):544. DOI: 10.1007/s12020-017-1269-6
Burrows N, Babur M, Resch J, et al. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1 a (HIF-1 a) pathways. J Clin Endocrinol Metab. 2011;96(12):E1934-43. DOI: 10.1210/jc.2011-1426
Ma X Wang Q, Liu F, et al. KLF5 promotes the tumori-genesis and metastatic potential of thyroid cancer cells through the NF-kB signaling pathway. Oncol Rep. 2018;40(5):2608-2618. DOI: 10.3892/or.2018.6687
Xing M. Genetic alterations in the phosphatidylino-sitol-3 kinase/Akt pathway in Thyroid cancer. Thyroid. 2010;20(7):697-706. DOI: 10.1089/thy.2010.1646
Mondragon-Teran P, Lopez-Hernandez LB, Gutierrez-Sali-nas J. et al. Intracellular signalling mechanisms in thyroid cancer. Cirugia y Cirujano. 2016;84(5):434-443
Byeon HK, Na HJ, Yang YJ, et al. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition. Mol Carcinog. 2016;55(11):1678-1687. Epub 2015 Oct 12. DOI: 10.1002/mc.22418
Jing FJ, Liang J, Liang ZY et al. BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma. Chin Med J (Engl). 2013;126(16):3013-8.
Bommarito A, Richiusa P, Carissimi E, et al. BRAFV600E mutation, TIMP-1 upregulation, and NF-kB activation: closing the loop on the papillary thyroid cancer trilogy. Endocr Relat Cancer. 2011;18(6):669-85. 10.1530/ ERC-11-0076. DOI: 10.1530/ERC-11-0076
Спирина Л.В., Чижевская С.Ю., Кондакова И.В. Экспрессия транскрипционных, ростовых факторов и компонентов AKT/m-TOR сигнального пути в ткани папиллярного рака щитовидной железы. // Проблемы эндокринологии. - 2018. - Т 64. - № 4. - С.208-215. DOI: 10.14341/probl9310
Givens DJ, Buchmann LO, Agarwal AM, et alBRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope. 2014 Sep;124(9):E389-93. DOI: 10.1002/lary.24668
Shen G1, Kou X Liu B, Huang R, et al. BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases. Clin Nucl Med. 2018 Jul;43(7):e215-e219.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019